Daniel Vitt
Chief Executive Officer at IMMUNIC, INC.
Net worth: 515 958 $ as of 2024-03-30
Profile
Daniel Vitt is the founder of Brauhaus Germering GmbH, established in 2018, where he holds the title of Managing Director.
He was also the founder of 4SC AG, founded in 1997, where he served as the Chief Scientific & Development Officer from 2014 to 2016.
Currently, Dr. Vitt holds the position of President, Chief Executive Officer & Director at Immunic AG since 2017.
He is also the President, Chief Executive Officer & Director at Immunic, Inc. since 2019.
Additionally, he serves as the Deputy Chairman-Supervisory Board at Weltoffen-Germering Weltladen eG since 2008 and as the Managing Director at 4SC Discovery GmbH.
He is also the Managing Director at Immunic Research GmbH, Listrax Ug, and a Member-Supervisory Board at quattro research GmbH.
In his former roles, Dr. Vitt was the President, Chief Executive Officer & Director at Vital Therapies, Inc. and a Director at Nexigen GmbH.
Dr. Vitt obtained his doctorate degree from Julius-Maximilians-Universität Würzburg in 1998.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IMMUNIC, INC.
0.43% | 2024-03-03 | 390,877 ( 0.43% ) | 515 958 $ | 2024-03-30 |
Daniel Vitt active positions
| Companies | Position | Start |
|---|---|---|
| IMMUNIC, INC. | Chief Executive Officer | 2016-12-31 |
| Weltoffen-Germering Weltladen eG | Director/Board Member | 2010-05-09 |
4SC Discovery GmbH
 4SC Discovery GmbH BiotechnologyHealth Technology 4SC Discovery GmbH provides research and development services in biology. The company is headquartered in Planegg-Martinsried, Germany. | Chief Tech/Sci/R&D Officer | 2011-12-31 |
Immunic AG
 Immunic AG Pharmaceuticals: MajorHealth Technology Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany. | Chief Executive Officer | 2017-01-08 |
quattro research GmbH
 quattro research GmbH Miscellaneous Commercial ServicesCommercial Services Quattro Research GmbH is an interdisciplinary team of scientists and IT professionals that provides IT solutions for research and development. The private company is based in Martinsried, Germany. The German company specializes in bioregistration and handles antibodies and other macromolecules. The company also offers products such as the HELM hierarchical editing language for macromolecules and an electronic lab journal. Quattro/CM is their software that helps manage inventory easily. | Director/Board Member | - |
| Immunic Research GmbH | Chief Executive Officer | - |
| Brauhaus Germering GmbH | Chief Executive Officer | 2017-12-31 |
| Listrax Ug | Chief Executive Officer | - |
Former positions of Daniel Vitt
| Companies | Position | End |
|---|---|---|
| 4SC AG | Founder | 2016-12-30 |
| ░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
| ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Training of Daniel Vitt
| Julius-Maximilians-Universität Würzburg | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| 4SC AG | Health Technology |
| IMMUNIC, INC. | Health Technology |
| Private companies | 9 |
|---|---|
Vital Therapies, Inc.
 Vital Therapies, Inc. Pharmaceuticals: MajorHealth Technology Vital Therapies, Inc. operates as a biotherapeutic company, which develops a cell-based therapy targeting the treatment of acute forms of liver failure. Its product candidate, ELAD System, is a human cell-based bio-artificial liver support system that operates outside the body or extracorporeal. The company was founded in May 2003 and is headquartered in San Diego, CA. | Health Technology |
| Weltoffen-Germering Weltladen eG | |
Nexigen GmbH
 Nexigen GmbH Pharmaceuticals: MajorHealth Technology Nexigen GmbH identifies and develops peptide based therapeutics for cancer. It focuses on the development of pathways to create transformative cancer therapies. The firm's technologies give access to drug targets which pose significant challenges to conventional discovery approaches. The company was founded by Annette Friebe, Burckhard Heil, and Claudia Carl in 2007 and is headquartered in Cologne, Germany. | Health Technology |
4SC Discovery GmbH
4SC Discovery GmbH BiotechnologyHealth Technology 4SC Discovery GmbH provides research and development services in biology. The company is headquartered in Planegg-Martinsried, Germany. | Health Technology |
quattro research GmbH
quattro research GmbH Miscellaneous Commercial ServicesCommercial Services Quattro Research GmbH is an interdisciplinary team of scientists and IT professionals that provides IT solutions for research and development. The private company is based in Martinsried, Germany. The German company specializes in bioregistration and handles antibodies and other macromolecules. The company also offers products such as the HELM hierarchical editing language for macromolecules and an electronic lab journal. Quattro/CM is their software that helps manage inventory easily. | Commercial Services |
Immunic AG
Immunic AG Pharmaceuticals: MajorHealth Technology Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany. | Health Technology |
| Immunic Research GmbH | |
| Brauhaus Germering GmbH | |
| Listrax Ug |
- Stock Market
- Insiders
- Daniel Vitt
